biostudies-literatureDas RNIDDK NIH HHSNational Institute of Diabetes and Digestive and Kidney DiseasesNIGMS NIH HHS886-897https://www.ebi.ac.uk/biostudies/studies/S-EPMC8407441biostudies-literatureUnknown20(4)<h4>Background & aims</h4>The assessment of therapeutic response after neoadjuvant treatment and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) has been an ongoing challenge. Several limitations have been encountered when employing current grading systems for residual tumor. Considering endoscopic ultrasound (EUS) represents a sensitive imaging technique for PDAC, differences in tumor size between preoperative EUS and postoperative pathology after neoadjuvant therapy were hypothesized to represent an improved marker of treatment response.<h4>Methods</h4>For 340 treatment-naïve and 365 neoadjuvant-treated PDACs, EUS and pathologic findings were analyzed and correlated with patient overall survival (OS). A separate group of 200 neoadjuvant-treated PDACs served as a validation cohClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationTumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome.PMC8407441P30 DK120531U54 GM104942Uttam SPaniccia AOngchin MCBahary NDas RMcGrath KPingpank JFKhalid AOhori NPShyu SSingh HHenn PHogg MEDasyam AKGorantla VCThomas RZeh HJRhee JCBrand REZureikat AHChennat JSSlivka ASarkaria SBoone BAEllsworth SLandau MSSmith KTheisen BKSeiser NSinghi ADLee KKFasanella KEfalseTumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome.<h4>Background & aims</h4>The assessment of therapeutic response after neoadjuvant treatment and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) has been an ongoing challenge. Several limitations have been encountered when employing current grading systems for residual tumor. Considering endoscopic ultrasound (EUS) represents a sensitive imaging technique for PDAC, differences in tumor size between preoperative EUS and postoperative pathology after neoadjuvant therapy were hypothesized to represent an improved marker of treatment response.<h4>Methods</h4>For 340 treatment-naïve and 365 neoadjuvant-treated PDACs, EUS and pathologic findings were analyzed and correlated with patient overall survival (OS). A separate group of 200 neoadjuvant-treated PDACs served as a validation coh2022-01-01T00:00:00Z2022 Apr2025-04-22T11:54:30.991Z2025-04-06T00:06:21.833ZS-EPMC84074413327857310.1016/j.cgh.2020.11.041